Loading company
Neumora Therapeutics, Inc.
NMRA · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026
$0.69+2.1%Sep 28 close
- 1M
- -50.2%
- 6M
- -70.3%
- 1Y
- -60.7%
NMRA · Nasdaq · Healthcare · Biotechnology
Next earnings: November 5, 2026
$0.69+2.1%Sep 28 close
Neumora Therapeutics, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$43.1M | -$52.7M | +18.30% |
| Profit per share | -$0.23 | -$0.33 | +30.30% |
| Free Cash Flow | -$51.5M | -$30.4M | -69.42% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Neumora Therapeutics, Inc. has no earnings call transcript available.
“We delivered another quarter of disciplined execution against our strategic priorities, advancing key programs across our pipeline and positioning Neumora for a series of meaningful clinical milestones,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the greatest medical challenges of our generation by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Neumora Therapeutics, Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.